Aldenhoff Y B, van Der Veen F H, ter Woorst J, Habets J, Poole-Warren L A, Koole L H
Center for Biomaterials Research, University of Maastricht, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
J Biomed Mater Res. 2001 Feb;54(2):224-33. doi: 10.1002/1097-4636(200102)54:2<224::aid-jbm9>3.0.co;2-e.
A porous polyurethane vascular prosthesis with an internal diameter of 5 mm was studied. The graft carries a coating of immobilized dipyridamole (Persantin(R)) on the surface of its lumen. Dipyridamole is a potent nontoxic inhibitor of platelet activation/aggregation, and also a strong inhibitor of vascular smooth muscle cell proliferation. The polyurethane material is also known as Chronoflex(R), and already finds use as a vascular access graft. The coated vascular graft was studied in vitro (hemocompatibility, interaction with blood platelets and cultured endothelial cells), as well as in two established in vivo models. In the first in vivo study, coated grafts were implanted in goats, as a bypass of the carotid artery (four animals, eight grafts, length of the graft was approximately 12 cm). Four uncoated grafts were used as controls in otherwise identical experiments. In the second in vivo experiment, eight sheep were used. Each animal received one coated and one uncoated prosthesis as an interposition graft in the carotid artery (length of the graft was 4 cm). The in vitro experiments revealed that the dipyridamole coating has three beneficial effects: reduced thrombogenicity, reduced adherence of blood platelets, and accommodation of a confluent monolayer of endothelial cells. The goat experiments showed patency of the coated grafts in three of the eight cases. The sheep experiments were not useful for the evaluation of the dipyridamole coating because deterioration of the polyurethane material was observed. The in vivo results indicate that the dipyridamole coating may positively influence the patency rate, probably because the coating promotes the growth of an endothelial cell lining. The sheep data show, however, that the limited stability of the Chronoflex(R) material precludes its issue for the construction of permanent small-bore vascular grafts.
研究了一种内径为5毫米的多孔聚氨酯血管移植物。该移植物在其管腔表面带有固定化双嘧达莫(潘生丁®)涂层。双嘧达莫是血小板活化/聚集的有效无毒抑制剂,也是血管平滑肌细胞增殖的强抑制剂。这种聚氨酯材料也被称为Chronoflex®,已被用作血管通路移植物。对这种涂层血管移植物进行了体外研究(血液相容性、与血小板和培养的内皮细胞的相互作用),以及在两种既定的体内模型中进行了研究。在第一项体内研究中,将涂层移植物植入山羊体内,作为颈动脉的旁路(四只动物,八个移植物,移植物长度约为12厘米)。在其他相同实验中,使用四个未涂层的移植物作为对照。在第二项体内实验中,使用了八只绵羊。每只动物在颈动脉中接受一个涂层和一个未涂层的假体作为插入移植物(移植物长度为4厘米)。体外实验表明,双嘧达莫涂层有三个有益效果:降低血栓形成性、减少血小板粘附以及容纳汇合的内皮细胞单层。山羊实验显示,八个案例中有三个涂层移植物保持通畅。绵羊实验对于评估双嘧达莫涂层没有用处,因为观察到聚氨酯材料出现了劣化。体内结果表明,双嘧达莫涂层可能对通畅率有积极影响,可能是因为该涂层促进了内皮细胞内衬的生长。然而,绵羊实验数据表明,Chronoflex®材料的有限稳定性使其无法用于构建永久性小口径血管移植物。